SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | AMGEN INC | 49,036,311 | 9.2% | EDGAR |
SC 13G/A | 2024-01-30 | STATE STREET CORP | AMGEN INC | - | 5.5% | EDGAR |
SC 13G/A | 2024-01-25 | BlackRock Inc. | AMGEN INC | 47,811,356 | 8.9% | EDGAR |
SC 13D | 2023-09-27 | AMGEN INC | Neumora Therapeutics, Inc. | 35,368,653 | 23.2% | EDGAR |
SC 13G/A | 2023-02-10 | AMGEN INC | Jasper Therapeutics, Inc. | 1,009,929 | - | EDGAR |
SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | AMGEN INC | 48,065,139 | 9.0% | EDGAR |
SC 13G/A | 2023-02-07 | BlackRock Inc. | AMGEN INC | 48,513,079 | 9.1% | EDGAR |
SC 13G/A | 2023-02-06 | STATE STREET CORP | AMGEN INC | - | 5.6% | EDGAR |
SC 13G | 2022-12-02 | AMGEN INC | NewAmsterdam Pharma Co N.V. | 4,910,000 | - | EDGAR |
SC 13G/A | 2022-02-11 | Capital Research Global Investors | AMGEN INC | 22,157,906 | 3.9% | EDGAR |
SC 13G/A | 2022-02-10 | STATE STREET CORP | AMGEN INC | - | 5.4% | EDGAR |
SC 13G/A | 2022-02-09 | VANGUARD GROUP INC | AMGEN INC | 46,661,009 | 8.3% | EDGAR |
SC 13G/A | 2022-02-01 | BlackRock Inc. | AMGEN INC | 50,046,345 | 8.9% | EDGAR |
SC 13G | 2022-01-12 | AMGEN INC | Vigil Neuroscience, Inc. | 3,206,281 | - | EDGAR |
SC 13G | 2021-10-01 | AMGEN INC | Jasper Therapeutics, Inc. | 2,700,000 | - | EDGAR |
SC 13G/A | 2021-02-16 | Capital Research Global Investors | AMGEN INC | 31,762,327 | 5.5% | EDGAR |
SC 13G/A | 2021-02-10 | VANGUARD GROUP INC | AMGEN INC | 47,227,229 | 8.1% | EDGAR |
SC 13G/A | 2021-02-05 | AMGEN INC | Provention Bio, Inc. | 2,500,000 | - | EDGAR |
SC 13G/A | 2021-02-05 | AMGEN INC | Akero Therapeutics, Inc. | 1,508,375 | - | EDGAR |
SC 13G | 2021-02-05 | STATE STREET CORP | AMGEN INC | - | 5.2% | EDGAR |